Abiomed Inc said European health regulators approved the use of its heart pump in cardiac surgery.
The Danvers, Massachusetts-based company said the device, called Impella cVAD, is expected to be commercially available in Europe by this summer.
The device is intended for use in cardiac surgery for supporting the weakened heart's left ventricle, which is responsible for pumping oxygen-rich blood from the lungs throughout the body.
Impella cVAD is still not approved in the United States.
Abiomed shares closed at $20.90 on Wednesday on the Nasdaq.
(Reporting by Anand Basu in Bangalore; Editing by Viraj Nair)
Trending On Reuters
Thirteen-year-old Siti Maryam says she suffers headaches and nausea after harvesting tobacco leaves with her bare hands during four years of working on her family's farm in Indonesia. Full Article